03-01-04

CASE G-970-9856F



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV365588629US Express Mail Label Number February 27, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ASCHER ET AL.

APPLICATION NO: 10/706,768

FILED: NOVEMBER 12, 2003

FOR: ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO-3-

(METHYLHYDRAZONO)METHYLCEPHALOSPORINS AND

INTERMEDIATES

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUBSTITUTE DECLARATION

Sir:

PCT application PCT/EP98/01890 claimed priority from three Austrian applications, two of which were not recited in the original U.S. Declaration. Enclosed is a Substitute Declaration reciting all three priority applications and a revised Application Data Sheet.

It is requested that the Substitute Declaration be entered and that the Filing Receipt refer to all three priority applications. In the event that a fee is required, the Commissioner is hereby authorized to charge said fee to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

Gabriel Lopez

Attorney for Applicants

Pog. No. 28 440

Reg. No. 28,440 (862) 778-7882

Date: February 27, 2004

Encl:

US	CASE 1 PG-9856/A/55/57/BCK
	FEB 2 7 2004 55
<u>DECL</u>	ARAGIONAMS POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION
□ C	riginal □ Supplemental ☑ Substitute
As a b	elow named inventor, I hereby declare that:
My res	sidence, post office address and citizenship are as stated below next to my name, and
and jo	ve I am the original, first and sole inventor (if only one name is listed below) or an original, first inventor (if more than one name is listed below) of the subject matter which is claimed and for a United States patent is sought on the invention entitled
	SACTERIAL SUBSTITUTED 7-ACYLAMINO-3-(METHYLHYDRAZONO)METHYL- ALOSPORINS AND INTERMEDIATES
the sp	ecification of which:
	is attached hereto.
×	was filed on 01.04.98 as Application No. 09/381758 (day/month/year)
	and, if this box (□) contains an ×
	was amended on(day/month/year)
	was filed as Patent Cooperation Treaty international Application No.
	(day/month/year)
	and, if this box (□) contains an ×
	entered the national stage in the United States and was accorded Application No.
	and, if this box (□) contains an ×

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

was amended, subsequent to entry into the national stage, on

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. § 1.56.

(day/month/year)

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIOR	PRIORITY CLAIMED	
AT	A546/97	01/04/97		□ No	
AT	A547/97	01/04/97	Yes	□ No	
AT	A548/97	01/04/97	Yes	□ No	
			☐ Yes	□ No	
			☐ Yes	□ No	

I hereby claim the benefit under 35 U.S.C. § 119 (e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE
	(day/month/year)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

United States	United States	Status (Pending,	International	
Application No.	Filing Date	Abandoned or U.S.	Application	and Filing
	(day/month/year)	Patent No.)	No.	Date

I hereby appoint the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If these brackets contain an X [X], I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Novartis Services AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to Michael W. Glynn, Novartis Corporation, Patent and Trademark Department, 564 Morris Avenue, Summit, NJ 07901-1027.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or first joint inventor

Gerd ASCHER

Inventor's signature

Date 04-11-700

Residence

6250∖Kundl, Austria

Citizenship

Austrian

Post Office Address

Daxerfeld 3 6250 Kundl Austria

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of second joint inventor, if any **Josef WIESER** Date OS/11
(day/month Inventor's signature Residence 6403 Polling, Austria Citizenship **Austrian** Post Office Address Siegfeld 92 6403 Polling Austria Full name of third joint inventor, if any Michael SCHRANZ Inventor's signature Residence 1200 Wien, Austria Citizenship Austrian Post Office Address **Burghardtgasse 7/18** 1200 Wien Austria Full name of fourth joint inventor, if any Johannes LUDESCHER Inventor's signature Residence 6252 Breitenbach, Austria Citizenship **Austrian** Post Office Address Kleinsoell 101 6252 Breitenbach

Austria

Full name of fifth joint inventor, if any	Johannes HILDEBRANDT		
Inventor's signature	flrames Molle-do	Date	05.11.2003 (day/month/year)
Residence	2512 Oeynhausen, Austria		
Citizenship	German		
Post Office Address	St. Laurentgasse 12 2512 Oeynhausen Austria		
Full name of sixth joint inventor, if any			
Inventor's signature		Date	(day/month/year)
Residence			
Citizenship			
Post Office Address			
Full name of seventh joint inventor, if any			
Inventor's signature		Date	(day/month/year)
			(day/month/year)
Residence			
Citizenship			

Post Office Address